The efficacy of poly‐ICLC against Ebola‐Zaire virus (EBOV) infection in mice and cynomolgus monkeys
Sign Up to like & getrecommendations! Published in 2019 at "Antiviral Research"
DOI: 10.1016/j.antiviral.2018.12.020
Abstract: ABSTRACT The potential protection of poly‐ICLC (Hiltonol®) a double stranded RNA (dsRNA) against EBOV infection was assessed with prophylactic and therapeutic administration to wild type and TLR3‐negative mice, and in non‐human primates (NHPs) by measuring… read more here.
Keywords: poly iclc; ebov infection; mice; iclc ... See more keywords
Poly-ICLC, a multi-functional immune modulator for treating cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Seminars in immunology"
DOI: 10.1016/j.smim.2020.101414
Abstract: Immunotherapies have become the first line of treatment for many cancer types. Unfortunately, only a small fraction of patients benefits from these therapies. This low rate of success can be attributed to 3 main barriers:… read more here.
Keywords: cancer; specific cells; poly iclc; tumor ... See more keywords
IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa222.385
Abstract: Abstract OBJECTIVE To assess safety and efficacy within a multi-center trial the H3.3K27M specific peptide vaccine with poly-ICLC in HLA-A02.01+ patients diagnosed with H3.3K27M+ DMGs. METHODS After focal radiation therapy, participants 3–21 years of age… read more here.
Keywords: poly iclc; 3k27m specific; specific peptide; peptide vaccine ... See more keywords
PDCT-17 (LTBK-11). PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M MIDLINE GLIOMAS
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz219.1200
Abstract: To assess within a multi-center trial the safety of H3.3K27M specific peptide vaccine in combination with poly-ICLC in HLA-A02.01+ patients diagnosed with H3.3K27M+ diffuse midline gliomas. Subjects 3–21 years of age with CLIA confirmed H3.3K27… read more here.
Keywords: poly iclc; 3k27m specific; treatment; specific peptide ... See more keywords
A phase I study of multi-HLA-binding HSP70 + GPC3 peptides and combination adjuvants of LAG3-Ig + Poly-ICLC against gastrointestinal cancers.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e15167
Abstract: e15167Background: Based on the exploratory analysis of our previous studies of peptide vaccine, we concluded that the combination of adjuvants hLAG-3Ig + Poly-ICLC is essential for controlling nega... read more here.
Keywords: poly iclc; study multi; multi hla; combination adjuvants ... See more keywords
A phase II trial of pembrolizumab and poly-ICLC in patients with metastatic mismatch repair-proficient colon cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e15552
Abstract: e15552 Background: Single agent programmed cell death protein 1 (PD1) inhibitor is ineffective against mismatch repair proficient (MMRp) colon cancer with response rates in single digits. Polyinosinic-Polycytidylic (Poly-ICLC) is a synthetic double stranded ribonucleic acid… read more here.
Keywords: response; poly iclc; colon cancer; trial ... See more keywords